Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

The US Food and Drug Administration last week approved Roche/Genentech's latest HER2-targeting breast cancer drug, trastuzumab emtansine (T-DM1).

NEW YORK (GenomeWeb News) – Dako today announced that the US Food and Drug Administration has approved its HER2 IQFISH pharmDx assay for marketing in the US.

Abbott, Merck Ink Companion Dx Deal to Personalize Unnamed Cancer Treatment

By Turna Ray
Ventana Medical Systems has been in a deal-making frenzy around companion diagnostics development.

This article has been updated from a previous version to clarify information about ongoing efforts to resolve the discordant results of the two studies.
By Ben Butkus

Continuing to expand the development program for its irreversible inhibitor of EGFR and HER2, afatinib, Boehringer Ingelheim Pharmaceuticals has launched two new Phase II studies — one investigating the drug as a treatment for inflammatory breast cancer and another for metastatic

Without speculating on a specific release date for the draft document, FDA's Elizabeth Mansfield said the companion diagnostics guidance is "definitely moving" through the agency.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.